BioSpace News Archive

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference.

Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that it has received a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (IGC-501).

Vistagen today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its Board of Directors.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia”) is excited to announce the acquisition of an initial 51% interest in Cosmetics Lab Ltd. (“CosLab”).

BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) announces that it has added Dr. John Paul SanGiovanni, world renowned nutritionist and Harvard-trained scientist, to its Medical and Scientific Advisory board.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated Transbiotech Biotechnology Research

StageZero Life Sciences, Ltd. (TSX: SZLS) (“StageZero” or the “Company”) today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.

OKYO Pharma Limited is pleased to announce that patients are now being dosed in the randomized portion of the phase 2, multi-center, double-masked, placebo-controlled trial of topical ocular OK-101 to treat DED.

Curative Biotechnology Inc., a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset licensing within the country.